Etanercept

Approved Uses

Etanercept is used to treat several chronic conditions caused by an overactive immune system. It helps reduce inflammation, manage symptoms, and in some cases, prevent permanent damage to joints or tissues.

Joint Conditions

• Rheumatoid Arthritis: Used for adults with moderate to severe active rheumatoid arthritis to reduce symptoms and slow joint damage.
• Polyarticular Juvenile Idiopathic Arthritis: Used for children and adolescents with moderate to severe active disease.
• Psoriatic Arthritis: Used for adults to improve physical function and limit joint damage.
• Ankylosing Spondylitis: Used for adults with active symptoms of this inflammatory spine condition.

Skin Conditions

• Plaque Psoriasis: Used for adults and children with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or light therapy (phototherapy).

This medication is often prescribed when other treatments have not been effective enough. It may be used alone or alongside other medications depending on the patient's specific diagnosis and medical history.

Mechanism of Action

Etanercept belongs to a class of drugs known as tumor necrosis factor (TNF) blockers. TNF is a protein naturally produced by the body's immune system. In a healthy person, TNF helps the body fight infections and heal injuries. However, in people with certain autoimmune conditions, the body produces too much TNF.

Excessive amounts of TNF lead to chronic inflammation, which can cause pain, swelling, and damage to various parts of the body, such as the joints or skin. Etanercept works by:

• Binding to TNF: The medication acts like a sponge, attaching itself to the excess TNF molecules circulating in the bloodstream.
• Blocking signals: By binding to TNF, etanercept prevents the protein from reaching and activating inflammatory receptors on the surface of cells.
• Reducing inflammation: Once the TNF is neutralized, the inflammatory response is lowered, which helps relieve symptoms like stiffness and swelling.

By controlling this overactive immune response, etanercept can help slow down the progression of joint destruction and improve physical function in patients with chronic inflammatory diseases.

Common Side Effects

The most frequently reported side effects of etanercept include:

• Redness, itching, pain, or swelling at the injection site
• Headache
• Nausea
• Dizziness
• Symptoms of a cold or upper respiratory infection, such as a runny nose or sore throat

Serious Side Effects

While less common, some side effects can be severe. Seek medical attention immediately if you experience:

• Signs of infection, such as fever, chills, cough, or persistent sore throat
• Nervous system problems, including numbness, tingling, vision changes, or weakness in the arms or legs
• New or worsening heart failure, characterized by shortness of breath or swelling of the ankles and feet
• Blood disorders, which may cause easy bruising, bleeding, or paleness
• Liver problems, such as yellowing of the skin or eyes, dark urine, or upper stomach pain
• Allergic reactions, including hives, facial swelling, or difficulty breathing
• New or worsening psoriasis, such as red, scaly patches or pus-filled bumps on the skin
• Lupus-like syndrome, which may cause joint pain or a rash on the cheeks or arms that worsens in the sun

Serious Infections

Etanercept can lower the ability of the immune system to fight infections. Some people have developed serious infections while taking this medication, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that have spread throughout the body. In some cases, these infections have been fatal. Healthcare providers typically test for TB before starting treatment and monitor for signs of infection during therapy.

Malignancy

There have been reports of lymphoma and other cancers in children and adolescents who received TNF blockers like etanercept. Some cases of unusual cancers, including those that were fatal, have been reported in this age group. Adults may also have an increased risk of certain skin cancers and should have regular skin examinations.

Neurological Events

Treatment with etanercept has been linked to new or worsening symptoms of demyelinating disorders, such as multiple sclerosis and optic neuritis. Seizures have also been reported. Individuals with a history of these conditions are usually monitored closely or advised to consider alternative treatments.

Blood Disorders

Rare but serious blood problems, including aplastic anemia and low levels of white blood cells or platelets, have occurred. Symptoms to watch for include persistent fever, bruising, bleeding, or paleness.

Heart Failure

Etanercept may cause new heart failure or worsen existing congestive heart failure. Monitoring for symptoms like shortness of breath or swelling of the ankles and feet is important for those with heart conditions.

Hepatitis B Reactivation

In people who carry the hepatitis B virus, the virus can become active again while using etanercept. This can lead to serious liver damage or death. Testing for hepatitis B is often performed before starting the medication.

Vaccinations and Latex

Live vaccines should not be administered while taking etanercept. Additionally, the needle cover of the prefilled syringe or the autoinjector may contain dry natural rubber (latex), which can cause allergic reactions in sensitive individuals.

Pregnancy

Information regarding the use of etanercept during pregnancy is limited. Studies have shown that the medication can cross the placenta and has been detected in the blood of infants born to mothers who received treatment during pregnancy. While some data from pregnancy registries have not shown a clear increase in the risk of major birth defects, the full safety profile for a developing fetus is not completely understood.

If you are pregnant or planning to become pregnant, it is important to discuss the potential benefits and risks of continuing treatment with your healthcare provider. Because the medication may remain in an infant's system for some time after birth, doctors may recommend delaying the administration of live vaccines to the baby for several months.

Breastfeeding

Etanercept is known to pass into human breast milk. It is currently unclear how much of the drug is absorbed by a nursing infant or what specific effects it may have on the child's development or health. Decisions regarding breastfeeding while using this medication should be made in consultation with a healthcare professional, considering both the mother's need for the drug and the potential risks to the infant.

Available Forms

Etanercept is administered as a subcutaneous injection. It is available in the following delivery formats:

• Prefilled syringes: These come ready for manual injection.
• Prefilled autoinjectors: These devices are designed to automate the injection process.
• Vials: These contain a liquid solution ready for withdrawal into a syringe.
• Vials for reconstitution: These contain a lyophilized powder that must be mixed with a diluent before use.
• Prefilled cartridges: These are used with a specific reusable autoinjector system.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) has approved etanercept for the treatment of several autoimmune and inflammatory conditions, including:

• Rheumatoid arthritis
• Polyarticular juvenile idiopathic arthritis in patients aged 2 years and older
• Psoriatic arthritis
• Ankylosing spondylitis
• Chronic moderate-to-severe plaque psoriasis in adults and children aged 4 years and older

Boxed Warning

Etanercept carries a boxed warning, the FDA's most serious type of warning, due to the following risks:

• Serious Infections: Patients are at increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis, bacterial sepsis, and invasive fungal infections. Patients should be tested for latent tuberculosis before starting treatment and monitored for active infection during therapy.
• Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept.

Regulatory Status of Biosimilars

The FDA has approved several biosimilar versions of etanercept. A biosimilar is a biologic product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. These biosimilars are approved for many of the same indications as the original reference medication.

Safety Communications

The FDA requires a Medication Guide to be provided with etanercept to inform patients about the potential for serious side effects. Healthcare providers are advised to monitor patients closely for new infections or signs of malignancy during and after treatment.

Factors Affecting Cost

Etanercept is a biologic medication that is typically dispensed through specialty pharmacies rather than standard retail pharmacies. The out-of-pocket cost for patients is determined by several factors, including the specific insurance plan's formulary, the patient's deductible, and the required copayment or coinsurance. Some insurance providers may require prior authorization or step therapy before covering the medication.

Biosimilars

Biosimilar versions of etanercept are available and may be offered at a lower price than the original reference product. These medications are highly similar to the original biologic and provide the same clinical benefits. Patients may wish to discuss with their healthcare provider or pharmacist whether a biosimilar is a more cost-effective option for their treatment plan.

Financial Assistance Programs

Because biologic therapies can be expensive, various financial support options are often available to help manage costs:

• Copay Savings Cards: Manufacturers may offer copay cards for patients with commercial insurance to help reduce monthly out-of-pocket expenses.
• Patient Assistance Programs: Non-profit organizations and manufacturers often provide programs for individuals who are uninsured or underinsured. These programs may provide the medication at a reduced cost or for free to those who meet specific income and eligibility requirements.